Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion
(Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and
refractory multiple myeloma.